Article Data

  • Views 747
  • Dowloads 127

Original Research

Open Access

Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer

  • Shun-Li Zhang1,*,
  • Ya-Qi Wang1
  • Jing-Hua Zhang1
  • Ji-Wei Hu1
  • Jie Ma1
  • Zheng Gu1
  • Yu Wang1
  • Jing-Jing Chen1

1Department of Breast Surgery, Tangshan People’s Hospital, 63001 Tangshan, China

DOI: 10.31083/j.ejgo.2021.03.2173 Vol.42,Issue 3,June 2021 pp.530-536

Submitted: 21 June 2020 Accepted: 21 December 2020

Published: 15 June 2021

*Corresponding Author(s): Shun-Li Zhang E-mail: zhangshunli@tom.com

Abstract

Objective: This study was conducted to determine the relationship between p16 gene methylation and expression of relevant receptors in breast cancer (BC) for subtyping the disease. Methods: Methylation-specific PCR (MSP) was carried out to detect the methylation status of p16 gene in 240 tissue samples and 205 serum samples from BC patients treated at our hospital. Immunohistochemistry was used to determine the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Receiver operating characteristics (ROC) curve was analyzed for diagnostic value based on methylation status for triple-negative (TN) BC. Results: The overall methylation rates of the p16 gene were 36.7% (88/240) and 35.1% (72/205) in the tissue and serum samples, respectively. In patients with ER, PR and HER2-TNBC, the methylation rate of the p16 gene was significantly higher than that in non-triple negative patients (84.9%, 62/73) vs (25.9%, 35/135, P < 0.01). The methylation of p16 gene was negatively associated with the expression of ER, PR and HER2 (r = -0.661, -0.694 and -0.765, respectively, P < 0.05), but it was not correlated with the pathological characteristics of BC, such as tumor grade and lymph-node metastasis. Receiver operator characteristic (ROC) curve analysis showed that p16 gene methylation had a significant diagnostic value for TNBC with an AUC of 0.815. Therefore, p16 gene methylation is associated with the subtype of TNBC and can be used as an easy and non-invasive approach to screen patients for TNBC.

Keywords

Breast cancer; Methylation; p16 gene; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor; Diagnostic value

Cite and Share

Shun-Li Zhang,Ya-Qi Wang,Jing-Hua Zhang,Ji-Wei Hu,Jie Ma,Zheng Gu,Yu Wang,Jing-Jing Chen. Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer. European Journal of Gynaecological Oncology. 2021. 42(3);530-536.

References

[1] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019; 144: 1941–1953.

[2] Li S, Li J, Li H, Gao M, Li N, Wang Y, et al. Clinicopathological and prognostic significance of TINCR in caner: a meta-analysis. Pathology-Research and Practice. 2019; 215: 152596.

[3] Hwang S, Park S, Kwon Y. Recent therapeutic trends and promis- ing targets in triple negative breast cancer. Pharmacology & Therapeutics. 2019; 199: 30–57.

[4] Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. the Breast. 2015; 24: S26–S35.

[5] Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nature Reviews Disease Primers. 2019; 5: 66.

[6] Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. Journal of Clinical Oncology. 2011; 29: 3885–3891.

[7] Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha

N. Therapeutic targets of triple-negative breast cancer: a review. British Journal of Pharmacology. 2015; 172: 4228–4237.

[8] de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, et al. Breast cancer immunology and immunotherapy. International Review of Cell and Molecular Biology. 2017; 331: 1–53.

[9] Kosok M, Alli-Shaik A, Bay BH, Gunaratne J. Comprehensive proteomic characterization reveals subclass-specific molecular aberrations within triple-negative breast cancer. IScience. 2020; 23: 100868.

[10] Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer. Surgical Oncology Clinics of North America. 2018; 27: 141–153.

[11] Guo Y, Hu Y, Qiao M, Wang Y, Yu J, Li J, et al. Radiomics analysis on ultrasound for prediction of biologic behavior in breast invasive ductal carcinoma. Clinical Breast Cancer. 2018; 18: e335– e344.

[12] Fontes-Sousa M, Lobo J, Lobo S, Salta S, Amorim M, Lopes P, et al. Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal a/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence. Molecular Medicine. 2020; 26: 22.

[13] Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: from early detection to new therapies. Radiología. 2017; 59: 368–379.

[14] Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Review of Proteomics. 2019; 16: 93–103.

[15] Schwamborn K. Imaging mass spectrometry in biomarker discovery and validation. Journal of Proteomics. 2012; 75: 4990–4998.

[16] Pusztai L. Current status of prognostic profiling in breast cancer. The Oncologist. 2008; 13: 350–360.

[17] Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, et al. Aber- rant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research. 2003; 63: 4174–4180.

[18] Meng R, Li Y, Chen X, Huang Y, Shi H, Du D, et al. Aberrant methylation of RASSF1a closely associated with HNSCC, a meta- analysis. Scientific Reports. 2016; 6: 20756.

[19] Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. International Journal of Cancer. 2003; 107: 970–975.

[20] Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MJ, Lahti- Domenici J, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clinical Cancer Research. 2004; 10: 3104–3109.

[21] Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology. 1998; 16: 1197–1206.

[22] Harbhajanka A, Lamzabi I, Bitterman P, Reddy VB, Ghai R, Gattuso P. Correlation of p16 expression on cancer and stromal cells with clinicopathologic and immunohistochemical features of lobular breast carcinoma. Applied Immunohistochemistry & Molecular Morphology. 2019; 27: 658–662.

[23] Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics. 1994; 8: 22–26.

[24] Wang P, Pei R, Lu Z, Rao X, Liu B. Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma. Journal of the Chinese Medical Association. 2013; 76: 135–139.

[25] Lin SY, Yeh KT, Chen WT, Chen HC, Chen ST, Chiou HY, et al. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncology Reports. 2004; 11: 341–348.

[26] Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research. 2007; 9: R57.

[27] Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. British Journal of Cancer. 1998; 78: 1661–1668.

[28] Milde-Langosch K, Bamberger A, Methner C, Rieck G, Löning T. Expression of cell cycle-regulatory proteins Rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. International Journal of Cancer. 2000; 87: 468–472.

[29] Silva JM, Dominguez G, Villanueva MJ, Gonzalez R, Garcia JM, Corbacho C, et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. British Journal of Cancer. 1999; 80: 1262–1264.

[30] Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. Journal of Clinical Oncology. 2006; 24: 4262–4269.

[31] Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W. Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. PLoS ONE. 2018; 13: e0199091.

[32] Brebi-Mieville P, Ili-Gangas C, Leal-Rojas P, Noordhuis MG, Soudry E, Perez J, et al. Clinical and public health research using methylated DNA immunoprecipitation (MeDIP): a comparison of commercially available kits to examine differential DNA methylation across the genome. Epigenetics. 2012; 7: 106–112.

[33] Shan M, Yin H, Li J, Li X, Wang D, Su Y, et al. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget. 2016; 7: 18485–18494.

[34] Claus R, Wilop S, Hielscher T, Sonnet M, Dahl E, Galm O, et al. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics. 2012; 7: 772–780.

[35] Dietrich D. DNA methylation analysis from body fluids. Urothelial Carcinoma. 2018; 60: 239–249.

[36] Jung M, Uhl B, Kristiansen G, Dietrich D. Bisulfite conversion of DNA from tissues, cell lines, buffy coat, FFPE tissues, microdissected cells, swabs, sputum, aspirates, lavages, effusions, plasma, serum, and urine. Methods in Molecular Biology. 2015; 104: 139– 159.

[37] Huang Y, Wei L, Zhao R, Liang W, Zhang J, Ding X, et al. Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes. Journal of Cancer. 2018; 9: 2203–2210.

[38] Kozomara Z, Supic G, Krivokuca A, Magic Z, Dzodic R, Milovanovic Z, et al. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia. Journal of B.U.ON. 2018; 23: 684–691.

[39] Goyal A, Sahu RK, Kumar M, Sharma S, Qayyum S, Kaur N, et al. p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma. Journal of Cancer Research and Therapeutics. 2019; 15: 1147–1154.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top